The rationale for targeting BTK is that it allows selective inhibition of the auto-reactive B cells that are behind the pathologies of MS, myasthenia gravis and other autoimmune disorders.

New York–based hematologist-oncologist and clinical researcher works to lower the barriers to enrolling in clinical trials.

Nurix Therapeutics, Inc. stock slid 40% after promising NX-5948 results in CLL. NX-5948 shows efficacy in heavily pre-treated ...

Dr Annalisa Morgan previews discussions on disease-modifying therapies, emerging treatments such as CAR T-cell therapy, and ...

Sellas Life Sciences (SLS) announced data from Phase 2a trial of SLS009 – tambiciclib -, a highly selective CDK9 inhibitor, in ...

During a Case-Based Roundtable® event, Nitin Jain, MD, and participants discussed treating a patient with CLL after ...